Skip to main content
    N

    Neuraxis, Inc. (NRXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $4.83
    -0.59 (-10.89%)

    Market Cap: $76.93M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Neuraxis, Inc. (NRXS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Neuraxis reported revenue of $3.57M for the fiscal year ended Dec 31, 2025, up 32.9% from the year before. That year, net income was -$7.80M with a net margin of -218.5%, operating cash flow was -$6.43M and free cash flow was -$6.46M. The quarter ended Sep 30, 2026 had revenue of $2.03M and net income of -$6.55M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from $1.93M, a compound annual rate of 13.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.57M+32.9%84.2%-219.4%-218.5%
    Dec 2024$2.69M+9.2%86.5%-266.5%-306.8%
    Dec 2023$2.46M-8.4%87.7%-270.9%-594.6%
    Dec 2022$2.68M-1.3%88.9%-125.6%-178.0%
    Dec 2021$2.72M+41.0%82.8%-109.1%-111.3%
    Dec 2020$1.93MN/A75.1%-213.5%-193.0%
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$3.57M$2.69M$2.46M$2.68M$2.72M$1.93M
    Cost of revenue$562.92K$362.00K$303.35K$297.06K$467.66K$481.09K
    Gross profit$3.01M$2.32M$2.16M$2.39M$2.25M$1.45M
    Research and development$493.61K$433.61K$169.31K$225.61K$203.41K$166.80K
    Operating income-$7.83M-$7.16M-$6.66M-$3.37M-$2.97M-$4.12M
    Net income-$7.80M-$8.24M-$14.63M-$4.78M-$3.03M-$3.73M
    EBITDA-$7.67MN/A-$696.74KN/A-$2.95M-$3.61M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.03M$1.93M$1.61M$968.13K$811.41K$894.09K$895.65K$761.16K$666.63K$611.50K$646.63K$531.46K
    Gross profit$1.76M$1.66M$1.39M$826.82K$675.93K$747.44K$756.18K$644.75K$569.58K$538.04K$571.55K$459.11K
    Operating income-$6.58M-$2.12M-$1.74M-$1.72M-$2.10M-$1.72M-$2.30M-$1.47M-$1.65M-$2.21M-$1.83M-$1.63M
    Net income-$6.55M-$2.09M-$1.76M-$1.71M-$2.12M-$1.69M-$2.28M-$1.45M-$1.76M-$2.92M-$2.12M-$1.59M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $148.29K by $4.82M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$6.40M$4.76M$509.50K$1.48M$760.48K$2.79M
    Current assets$5.73M$4.27M$242.61K$476.96K$491.01K$2.46M
    Cash and equivalents$4.97M$3.70M$78.56K$253.70K$320.86K$1.90M
    Total liabilities$3.00M$2.69M$1.91M$7.05M$1.59M$1.15M
    Short-term debt$148.29K$154.15K$148.06K$489.23K$277.99K$174.32K
    Long-term debtN/AN/AN/AN/A$51.69KN/A
    Shareholder equity$3.40M$2.07M-$1.40M-$5.57M-$825.66K$1.64M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$6.66M$10.00M$8.75M$6.40M$5.78M$7.09M$3.03M$4.76M$1.14M$2.63M$945.73K$509.50K
    Total liabilities$3.03M$3.26M$3.00M$3.00M$3.49M$2.83M$2.77M$2.69M$2.94M$7.89M$4.13M$1.91M
    Cash and equivalents$4.48M$8.32M$7.08M$4.97M$4.38M$5.99M$2.01M$3.70M$260.88K$1.77M$81.75K$78.56K
    Shareholder equity$3.62M$6.74M$5.75M$3.40M$2.28M$4.25M$258.48K$2.07M-$1.79M-$5.26M-$3.18M-$1.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$6.43M-$6.10M-$6.69M-$2.30M-$2.23M-$4.14M
    Capital expenditures$31.15K$27.78K$30.78K$1.39K$1.39K$27.72K
    Free cash flow-$6.46M-$6.13M-$6.72M-$2.30M-$2.24M-$4.17M
    Investing cash flow-$131.15K-$27.78K-$71.78K-$61.20K-$1.39K-$27.72K
    Financing cash flow$7.83M$9.74M$6.59M$2.29M$661.10K$6.05M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.27M-$1.03M-$1.23M-$1.93M-$1.43M-$1.47M-$1.60M-$1.76M-$1.39M-$1.62M-$1.33M-$2.63M
    Capital expendituresN/A$6.30K$0$5.86K$0$7.29K$18.00K$0$4.37K$8.69K$14.72K$16.04K
    Free cash flowN/A-$1.04M-$1.23M-$1.94M-$1.43M-$1.47M-$1.62M-$1.76M-$1.40M-$1.62M-$1.35M-$2.65M
    Last 12 quarters

    Frequently Asked Questions About NRXS

    What is Neuraxis' annual revenue?

    Neuraxis reported revenue of $3.57M for the fiscal year ended Dec 31, 2025.

    How fast is Neuraxis' revenue growing?

    Revenue was up 32.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.0%.

    Is Neuraxis profitable?

    No. Neuraxis reported net income of -$7.80M for the fiscal year ended Dec 31, 2025, with a net margin of -218.5%.

    How much free cash flow does NRXS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$6.43M minus capital expenditures of $31.15K produced free cash flow of -$6.46M.

    How much debt does Neuraxis have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $148.29K and cash and equivalents of $4.97M.